TELIX PHARMACEUTICTELIX PHARMACEUTICTELIX PHARMACEUTIC

TELIX PHARMACEUTIC

No trades
See on Supercharts
Next report date
Report period
H1 2024
EPS estimate
0.63MXN
Revenue estimate
‪3.81 B‬MXN
Market capitalization
‪56.16 B‬MXN
‪60.26 M‬MXN
‪5.81 B‬MXN
‪248.84 M‬
Beta (1Y)
1.24

About TELIX PHARMACEUTICALS LIMITED

CEO
Christian P. Behrenbruch
Headquarters
Melbourne
Founded
2017
ISIN
AU000000TLX2
FIGI
BBG01MFRGWT5
Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialisation. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TX250, TX591, and TX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

Depending on the exchange, the stock ticker may vary. For instance, on BMV exchange TELIX PHARMACEUTIC stocks are traded under the ticker TLX1/N.
TELIX PHARMACEUTIC is going to release the next earnings report on Aug 22, 2024. Keep track of upcoming events with our Earnings Calendar.
TLX1/N stock is 0% volatile and has beta coefficient of 1.24. Track TELIX PHARMACEUTIC stock price on the chart and check out the list of the most volatile stocks — is TELIX PHARMACEUTIC there?
TLX1/N earnings for the last quarter are −0.51 MXN per share, whereas the estimation was 0.64 MXN resulting in a −181.00% surprise. The estimated earnings for the next quarter are 0.85 MXN per share. See more details about TELIX PHARMACEUTIC earnings.
TELIX PHARMACEUTIC revenue for the last quarter amounts to ‪2.52 B‬ MXN despite the estimated figure of ‪2.52 B‬ MXN. In the next quarter revenue is expected to reach ‪3.24 B‬ MXN.
Yes, you can track TELIX PHARMACEUTIC financials in yearly and quarterly reports right on TradingView.
TLX1/N stock hasn't changed in a week, the last month showed zero change in price, over the last year there was no change in TELIX PHARMACEUTIC price.
TLX1/N net income for the last quarter is ‪225.84 M‬ MXN, while the quarter before that showed ‪−163.47 M‬ MXN of net income which accounts for 238.15% change. Track more TELIX PHARMACEUTIC financial stats to get the full picture.
Today TELIX PHARMACEUTIC has the market capitalization of ‪56.16 B‬, it has increased by 12.05% over the last week.
No, TLX1/N doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, TLX1/N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade TELIX PHARMACEUTIC stock right from TradingView charts — choose your broker and connect to your account.
TLX1/N reached its all-time high on Apr 23, 2024 with the price of 138.77 MXN, and its all-time low was 138.77 MXN and was reached on Apr 23, 2024. View more price dynamics on TLX1/N chart.
See other stocks reaching their highest and lowest prices.
We've gathered analysts' opinions on TELIX PHARMACEUTIC future price: according to them, TLX1/N price has a max estimate of 211.63 MXN and a min estimate of 148.25 MXN. Watch TLX1/N chart and read a more detailed TELIX PHARMACEUTIC stock forecast: see what analysts think of TELIX PHARMACEUTIC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. TELIX PHARMACEUTIC EBITDA is ‪675.72 M‬ MXN, and current EBITDA margin is 11.63%. See more stats in TELIX PHARMACEUTIC financial statements.